Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in ...
A first look at Canon-powered Vaonis Hyperia – a smart telescope that brings professional observatory-level astrophotography ...
A new and astonishing development has been revealed as the Pyxis Ocean has been testing the WindWing system, which provides ...
Trapped in a hell he helped make, a lone hacker aboard a space station far from home sneaks and fights his way through horrible mutants and killer robots in order to take down the monstrous artificial ...
The initial funding round underscores growing investor confidence in decarbonising regional port and shipping operations. SINGAPORE - Media OutReach Newswire - 22 December 2025 - Pyxis, a leading ...
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...
Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...
BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback